Slide 1: Q3/9M 2025 Results Presentation
Q3/9M 2025 Results Presentation Dietmar Siemssen Wolf Lehmann
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or
Slide 3: Q3 and 9M 2025 Overview
Q3 and 9M 2025 Overview Dietmar Siemssen (CEO)
Slide 4: 9M/Q3 2025 – Lower than Expected Growth and Profitability
9M/Q3 2025 – Lower than Expected Growth and Profitability 2025 Guidance adjusted despite stronger Q4 3Q 2025 Results 9 Months YTD (9M) 2025 Results Revenues (EURm) Adjusted EBITDA (EURm) Revenues (EURm) Adjusted EBITDA (EURm) Organic growth yoy1 -1.2% Organic growth yoy1 -9.4% Organic growth yoy1 -1
Slide 5: People – Changes in the Leadership Team to Accelerate Transformation
People – Changes in the Leadership Team to Accelerate Transformation Wolf Lehmann Achim Schalk Hans-Norbert Topp Chief Financial Member of the Executive Vice President Officer Executive Board Moulded Glass September 2025 November 2025 August 2025 • Progressing on Moulded Glass (MG) separation; hired
Slide 6: Contributions to Profitable Growth in Q4 and Beyond
Contributions to Profitable Growth in Q4 and Beyond Return to operations, ramp-ups and continuous shift to high value products Furnace upgrade Ramp up of new lines Production qualified by completed in May 2025 from expansion project key customer Lohr | Moulded Glass Pharma, F&B Morganton | Vials Sko
Slide 7: ESG Ratings
ESG Ratings Successful recognition of sustainability actions Top goal achieved CDP A- Rating ISS C+ Rating Sustainalytics MSCI AA-Rating Leadership PRIME status Low Risk Category 8.2/10 (2022 – 2025): ecovadis GOLD status FY 2025: First CSRD compliant sustainability report to be published; Report to
Slide 8: Financial Performance 9M and Q3 2025
Financial Performance 9M and Q3 2025 Wolf Lehmann (CFO)
Slide 9: 9M 2025 Development
9M 2025 Development Cosmetics and Oral Liquids Market Softness - Lower Demand for Bulk Vials 2024 figures on pro-forma basis Revenues (EURm) Adj. EBITDA (EURm) Adj. EPS (EURm) Organic growth yoy1 -1.8% Organic growth yoy1 -7.5% Organic growth yoy1 -32.5% 341 • Lower Oral Liquids revenues impacted ou
Slide 10: 9M 2025 Development: Operational view on KPIs by division
9M 2025 Development Operational view on KPIs by division Organic yoy In EURm & margin Revenues¹ Adj. EBITDA¹ +2.6% -6.6% 973 241 Plastic Packaging softness partially compensated by Medical 958 223 Devices 25.2% P&D 22.9% ▪ Revenues: Medical Devices (EUR +36m) driven by ramp-up of major projects (aut
Slide 11: Cash Flow Development YTD 2025
Cash Flow Development YTD 2025 Q3 with improved QoQ Free Cash Flow before M&A Operating Cash Flow Net CapEx Free Cash Flow before M&A 21 2 120 86 62 -28 -60 -65 -113 • EUR 96m in P&D –mainly growth -239 • EUR 27m in P&D – mainly for growth projects (EUR 65m) in Medical projects (EUR 19m) in Medical
Slide 12: Cash Flow Walk Q3 2025
Cash Flow Walk Q3 2025 • EUR 28m base and EUR 37m growth capex • EUR 27m in P&D – mainly for growth projects (EUR 19m) in Medical Devices and Syringe Systems 103 • EUR 34m in PPG – clear majority in Moulded Glass with focus on base capex (EUR 21m) 30 10 85 21 17 18 • EUR 10m in Q3; EUR 27m in 9M 25
Slide 13: Financing
Financing Reset Covenants and Reduced Bridge Loan by EUR 200m Net Financial Debt as of Q3 2025 Maturity Profile in EURm4 1.022 In EURm Q3 2025 Q3 2024 882 Revolving credit facilities1 102 380 347 257 691 Bridge loan 725 n.a. 146 Promissory loans 1,208 792 339 525 675 Local borrowings2 44 25 545 192
Slide 14: Summary
Summary Dietmar Siemssen (CEO)
Slide 15: Softer Q3/9M Necessitates Guidance Adjustment Despite Expected QoQ growth in Q4
Softer Q3/9M Necessitates Guidance Adjustment Despite Expected QoQ growth in Q4 Adjusted FY 2025 Guidance (organic; group level) Revenue Adjusted EBITDA Adj. EPS1 Old New Old New Old New FY 2025 -4% to -2% 18.5%-19% MDD% Growth Margin 2 Decline2 • Lower Business Performance in Q3 2025, in the Cosmet
Slide 16: Executive Summary
Executive Summary Q3 Results & Adjusted Guidance Results: continued market softness; Q3 and 9M with lower revenues and adj. EBITDA YoY; Q3 with EUR 21m positive free cash flow Guidance: FY 2025 organic revenue growth revised to -4% to -2% (prior: 0-2%); Adjusted EBITDA margin revised to 18.5% to 19%
Slide 17: Upcoming Events
Upcoming Events Financial Reporting and Conferences Financial Calendar Investor Conferences 2025 Jefferies Global Healthcare Conference Publication Annual February 26, 2026 18 November – London Report 2025 Deutsches Eigenkapitalforum 2025, Deutsche Börse Publication Quarterly 25 November – Frankfurt
Slide 18: Appendix
gerresheimer
Slide 19: Q3 2025 Development
Q3 2025 Development Cosmetics and Oral Liquids Market Softness - Lower Demand for Bulk Vials 2024 figures on pro-forma basis Revenues (EURm) Adj. EBITDA (EURm) Adj. EPS (EURm) Organic growth yoy1 -1.2% Organic growth yoy1 -9.4% Organic growth yoy1 -35.8% • Moulded Glass (EUR -13m): Cosmetics and Ora
Slide 20: Q3 2025 Development: Operational view on KPIs by division
Q3 2025 Development Operational view on KPIs by division Organic yoy In EURm & margin Revenues¹ Adj. EBITDA¹ +2.5% -7.0% 324 78 Ongoing weakness in Plastic Packaging 322 72 ▪ Revenues: Medical Devices revenue growth (EUR 13m) driven by 24.5% strong demand for medical devices such as autoinjectors; p
Slide 21: Reconciliation Q3 2025
Reconciliation Q3 2025 Reported and Adjusted Financials (Q3 2024 excluding Bormioli) Q3 2025 Q3 2024 Adjustments of EUR 30m include items related to In EUR m Reported Adjustment Adjusted Adjusted • Reorganization • ramp up of new capacities • integration of Bormioli Revenues 560.7 560.7 498.5 • etc.
Slide 22: Reconciliation 9M 2025
Reconciliation 9M 2025 Reported and Adjusted Financials (9M 2024 excluding Bormioli) 9M 2025 9M 2024 Adjustments of EUR 40m include items related to In EUR m Reported Adjustment Adjusted Adjusted • Reorganization • ramp up of new capacities • integration of Bormioli Revenues 1,681.4 1,681.4 1,467.0
Slide 23: innovating for a better life
innovating for a better life